EMA Authorised: Urorec (silodosin) — Recordati Ireland Ltd

View source ↗

Summary

EU marketing authorization has been granted for Urorec (silodosin) to treat benign prostatic hyperplasia. The marketing authorization holder is Recordati Irelan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Urorec (silodosin)

Snippet

Status: Authorised. Therapeutic area: Prostatic Hyperplasia. MAH: Recordati Ireland Ltd. Decision date: 06/05/2025